Iconovo
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreeme… Read more
Iconovo (ICO) - Net Assets
Latest net assets as of December 2025: Skr117.92 Million SEK
Based on the latest financial reports, Iconovo (ICO) has net assets worth Skr117.92 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr131.08 Million) and total liabilities (Skr13.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr117.92 Million |
| % of Total Assets | 89.96% |
| Annual Growth Rate | 34.1% |
| 5-Year Change | -13.95% |
| 10-Year Change | 1250.77% |
| Growth Volatility | 80.35 |
Iconovo - Net Assets Trend (2015–2025)
This chart illustrates how Iconovo's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Iconovo (2015–2025)
The table below shows the annual net assets of Iconovo from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr117.92 Million | -8.74% |
| 2024-12-31 | Skr129.21 Million | +13.82% |
| 2023-12-31 | Skr113.53 Million | +27.14% |
| 2022-12-31 | Skr89.29 Million | -34.84% |
| 2021-12-31 | Skr137.03 Million | +47.78% |
| 2020-12-31 | Skr92.73 Million | -14.77% |
| 2019-12-31 | Skr108.79 Million | +70.03% |
| 2018-12-31 | Skr63.99 Million | +102.97% |
| 2017-12-31 | Skr31.52 Million | +261.10% |
| 2016-12-31 | Skr8.73 Million | +39.26% |
| 2015-12-31 | Skr6.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Iconovo's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23371601400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr5.31 Million | 4.50% |
| Other Components | Skr347.18 Million | 294.42% |
| Total Equity | Skr117.92 Million | 100.00% |
Iconovo Competitors by Market Cap
The table below lists competitors of Iconovo ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kanger International Bhd
KLSE:0170
|
$5.15 Million |
|
Rubicon Technology Inc
PINK:RBCN
|
$5.15 Million |
|
Tira Austenite Tbk
JK:TIRA
|
$5.15 Million |
|
TARGETSPOT S.A. EO 1
F:6YW
|
$5.15 Million |
|
Biofish Holding AS
OL:BFISH
|
$5.15 Million |
|
Mountain Valley MD Holdings Inc
OTCQB:MVMDF
|
$5.14 Million |
|
IBC Advanced Alloys Corp
OTCQB:IAALF
|
$5.14 Million |
|
Melewar Industrial Group Bhd
KLSE:3778
|
$5.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Iconovo's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 129,212,000 to 117,922,000, a change of -11,290,000 (-8.7%).
- Net loss of 43,364,000 reduced equity.
- Share repurchases of 36,612,000 reduced equity.
- New share issuances of 36,612,000 increased equity.
- Other factors increased equity by 32,074,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-43.36 Million | -36.77% |
| Share Repurchases | Skr36.61 Million | -31.05% |
| Share Issuances | Skr36.61 Million | +31.05% |
| Other Changes | Skr32.07 Million | +27.2% |
| Total Change | Skr- | -8.74% |
Book Value vs Market Value Analysis
This analysis compares Iconovo's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.36x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.02x to 0.36x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr51.96 | Skr1.13 | x |
| 2016-12-31 | Skr1.52 | Skr1.13 | x |
| 2017-12-31 | Skr5.86 | Skr1.13 | x |
| 2018-12-31 | Skr9.83 | Skr1.13 | x |
| 2019-12-31 | Skr16.01 | Skr1.13 | x |
| 2020-12-31 | Skr11.93 | Skr1.13 | x |
| 2021-12-31 | Skr16.49 | Skr1.13 | x |
| 2022-12-31 | Skr10.09 | Skr1.13 | x |
| 2023-12-31 | Skr10.85 | Skr1.13 | x |
| 2024-12-31 | Skr8.07 | Skr1.13 | x |
| 2025-12-31 | Skr3.10 | Skr1.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Iconovo utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3924.34%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.11x
- Recent ROE (-36.77%) is below the historical average (-18.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -14.31% | -599.46% | 0.01x | 1.83x | Skr-1.52 Million |
| 2016 | 28.19% | 17.12% | 0.72x | 2.30x | Skr1.59 Million |
| 2017 | 4.61% | 7.24% | 0.48x | 1.34x | Skr-1.70 Million |
| 2018 | -6.71% | -36.06% | 0.16x | 1.14x | Skr-10.69 Million |
| 2019 | -10.12% | -93.77% | 0.10x | 1.05x | Skr-21.89 Million |
| 2020 | -18.48% | -96.30% | 0.18x | 1.09x | Skr-26.41 Million |
| 2021 | -19.09% | -169.77% | 0.10x | 1.08x | Skr-39.86 Million |
| 2022 | -56.34% | -293.93% | 0.14x | 1.36x | Skr-59.24 Million |
| 2023 | -40.43% | -648.37% | 0.06x | 1.13x | Skr-57.25 Million |
| 2024 | -31.84% | -1402.18% | 0.02x | 1.13x | Skr-54.06 Million |
| 2025 | -36.77% | -3924.34% | 0.01x | 1.11x | Skr-55.16 Million |
Industry Comparison
This section compares Iconovo's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $75,200,026
- Average return on equity (ROE) among peers: -74.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Iconovo (ICO) | Skr117.92 Million | -14.31% | 0.11x | $5.15 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| CellaVision AB (CEVI) | $20.07 Million | 13.08% | 1.20x | $262.59 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $65.69 Million | -72.50% | 0.20x | $13.78 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $93.64 Million | 22.63% | 0.57x | $56.67 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |